Pediatric acute lymphoblastic leukemia treatment protocols improvement: emphasis on minimal residual disease
Treatment of acute lymphoblastic leukemia (ALL) in children during the last 50 years has changed significantly, which has increased the survival of patients from 10–15 % in the early 60s to 80–85 % by the mid-2000s. Such results have been achieved through the development of new polychemotherapy regi...
Saved in:
| Main Authors: | M. A. Shervashidze, T. T. Valiev |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2020-10-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/427 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia
by: Fatima Hameed Ahmad, et al.
Published: (2024-09-01) -
Evaluation of Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Using EuroFlow Approaches
by: OA Beznos, et al.
Published: (2017-04-01) -
Diagnosis of Acute Lymphoblastic Leukemia Originating From T-Lineage Precursors and Approaches to Minimal Residual Disease Monitoring
by: OA Chernysheva, et al.
Published: (2018-12-01) -
Treatment of Pediatric Acute Lymphoblastic Leukemia in India as per modified BFM 95 protocol with Minimal Residual Disease monitoring
by: Dhwanee Thakkar, et al.
Published: (2025-12-01) -
Flow cytometric minimal residual disease monitoring in children with acute lymphoblastic leukemia treated by regimens with reduced intensity
by: A. M. Popov, et al.
Published: (2015-12-01)